ABBV vs SENS

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Senseonics (SENS) demonstrates strong operational execution with 87% YoY revenue growth in Q1 2026 and a strategic shift to direct European sales, strengthening its long-term competitive position. The unique 1-year Eversense sensor offers a significant market opportunity in the CGM space. However, the company continues to incur substantial net losses ($32.3M in Q1) and heavy cash burn. While recen...